"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Patient Information:
Details with Side Effects
Known hypersensitivity to any component of Menactra (polysaccharide diphtheria toxoid conjugate vaccine) vaccine including diphtheria toxoid, or a life-threatening reaction after previous administration of a vaccine containing similar components,16 are contraindications to vaccine administration.
Known hypersensitivity to dry natural rubber latex (see WARNINGS section) is a contraindication to vaccine administration.
16. Ball R, et al. Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System. CID 2001;32:1273-1280.
Last reviewed on RxList: 10/30/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Menactra Information
Menactra - User Reviews
Menactra User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.